Skip to main content
Hit enter to search or ESC to close
Search
Close Search
search
Menu
LP Portal
search
Menu
News
From investments to outcomes, stay connected to the people and companies
transforming Healthtech with us.
Portfolio
Lauxera
ESG & Impact
Compagnie:
All
Acandis
Antaros Medical
Biolamina
Caresyntax
Lifen
Lumicks
Matrix One
Natural Cycles
OrganOx
Ospi
Synovo group
Verdot
Fund:
All
Fund I
Fund II
Clear
Compagnie
Lauxera touche le jackpot avec OrganOx
Lauxera touche le jackpot avec OrganOx
Lauxera touche le jackpot avec OrganOx
29 August 2025
Terumo to acquire OrganOx Limited, a leading innovator in organ preservation devices, marking strategic entry into the organ transplantation-related sector
Terumo to acquire OrganOx Limited, a leading innovator in organ preservation devices, marking strategic entry into the organ transplantation-related sector
Terumo to acquire OrganOx Limited, a leading innovator in organ preservation devices, marking strategic entry into the organ transplantation-related sector
25 August 2025
Oxford university spinout OrganOx sold to Japanese group Terumo for $1.5bn
Oxford university spinout OrganOx sold to Japanese group Terumo for $1.5bn
Oxford university spinout OrganOx sold to Japanese group Terumo for $1.5bn
25 August 2025
La cession d’Organox à un industriel offre une première sortie éclatante à Lauxera Capital
La cession d’Organox à un industriel offre une première sortie éclatante à Lauxera Capital
La cession d’Organox à un industriel offre une première sortie éclatante à Lauxera Capital
25 August 2025
OrganOx réalise l’une des plus importantes sorties de fonds dans le secteur des technologies médicales au Royaume-Uni, générant un rendement record pour BGF
OrganOx réalise l’une des plus importantes sorties de fonds dans le secteur des technologies médicales au Royaume-Uni, générant un rendement record pour BGF
OrganOx réalise l’une des plus importantes sorties de fonds dans le secteur des technologies médicales au Royaume-Uni, générant un rendement record pour BGF
25 August 2025
Terumo Buying Organ Tech Provider OrganOx for$1.5 Billion
Terumo Buying Organ Tech Provider OrganOx for$1.5 Billion
Terumo Buying Organ Tech Provider OrganOx for$1.5 Billion
25 August 2025
Lauxera Capital Partners cède OrganOx pour 1,5 Md $
Lauxera Capital Partners cède OrganOx pour 1,5 Md $
Lauxera Capital Partners cède OrganOx pour 1,5 Md $
25 August 2025
Lauxera enregistre sa première sortie
Lauxera enregistre sa première sortie
Lauxera enregistre sa première sortie
25 August 2025
Terumo to acquire Organox Limited for approximately USD $1.5 billion
Terumo to acquire Organox Limited for approximately USD $1.5 billion
Terumo to acquire Organox Limited for approximately USD $1.5 billion
25 August 2025
Lauxera Capital Partners is proud to announce its investment in Antaros, a leading Swedish Imaging Drug Development Partner
Lauxera Capital Partners is proud to announce its investment in Antaros, a leading Swedish Imaging Drug Development Partner
Lauxera Capital Partners is proud to announce its investment in Antaros, a leading Swedish Imaging Drug Development Partner
15 July 2025
Lauxera Capital Partners Co-Leads a $142m Equity Investment Into OrganOx
Lauxera Capital Partners Co-Leads a $142m Equity Investment Into OrganOx
Lauxera Capital Partners Co-Leads a $142m Equity Investment Into OrganOx
24 February 2025
Lauxera Invests €50m in Acandis, a German, Neurovascular Medical Device Company Dedicated to the Prevention and Treatment of Stroke
Lauxera Invests €50m in Acandis, a German, Neurovascular Medical Device Company Dedicated to the Prevention and Treatment of Stroke
Lauxera Invests €50m in Acandis, a German, Neurovascular Medical Device Company Dedicated to the Prevention and Treatment of Stroke
22 January 2025
Lauxera Capital Partners Acquires Galen Data
Lauxera Capital Partners Acquires Galen Data
Lauxera Capital Partners Acquires Galen Data
25 November 2024
Synovo Group secures €12 million funding from Lauxera Capital Partners to accelerate growth and innovation in Healthtech transport software
Synovo Group secures €12 million funding from Lauxera Capital Partners to accelerate growth and innovation in Healthtech transport software
Synovo Group secures €12 million funding from Lauxera Capital Partners to accelerate growth and innovation in Healthtech transport software
24 September 2024
Biomedicaments : Verdot to invest €10 million in new plant in Puy-de-Dôme
Biomedicaments : Verdot to invest €10 million in new plant in Puy-de-Dôme
ESG & Impact
Biomedicaments : Verdot to invest €10 million in new plant in Puy-de-Dôme
23 September 2024
Natural cycles: $55m to consolidate its leadership in digital contraceptive health
Natural cycles: $55m to consolidate its leadership in digital contraceptive health
Natural cycles: $55m to consolidate its leadership in digital contraceptive health
3 June 2024
Natural Cycles Closes $55m Series C Financing Round Led by Lauxera Capital Partners
Natural Cycles Closes $55m Series C Financing Round Led by Lauxera Capital Partners
Natural Cycles Closes $55m Series C Financing Round Led by Lauxera Capital Partners
29 May 2024
Newsweek: World’s Best Digital Health Companies 2024
Newsweek: World’s Best Digital Health Companies 2024
Newsweek: World’s Best Digital Health Companies 2024
14 May 2024
OSPI wants to optimize the use of hospital data with AI
OSPI wants to optimize the use of hospital data with AI
OSPI wants to optimize the use of hospital data with AI
2 October 2023
Creation of Ospi, the result of the merger between Groupe PSIH and Collective Thinking
Creation of Ospi, the result of the merger between Groupe PSIH and Collective Thinking
Creation of Ospi, the result of the merger between Groupe PSIH and Collective Thinking
26 September 2023
Lauxera Capital Partners invests €17 million in Swedish regenerative medicine leader BioLamina AB
Lauxera Capital Partners invests €17 million in Swedish regenerative medicine leader BioLamina AB
Lauxera Capital Partners invests €17 million in Swedish regenerative medicine leader BioLamina AB
12 September 2023
Lauxera Capital Partners has led a £25m growth investment into OrganOx
Lauxera Capital Partners has led a £25m growth investment into OrganOx
Lauxera Capital Partners has led a £25m growth investment into OrganOx
17 July 2023
Caresyntax, Relyens and Intel are collaborating to launch the Connected Surgery program
Caresyntax, Relyens and Intel are collaborating to launch the Connected Surgery program
Caresyntax, Relyens and Intel are collaborating to launch the Connected Surgery program
9 May 2023
Purification: Auvergne, France-based Verdot changes hands
Purification: Auvergne, France-based Verdot changes hands
Purification: Auvergne, France-based Verdot changes hands
13 September 2022
Lauxera Capital Partners invests €10m in German Medtech software company Matrix Requirements
Lauxera Capital Partners invests €10m in German Medtech software company Matrix Requirements
Lauxera Capital Partners invests €10m in German Medtech software company Matrix Requirements
16 June 2022
Leading MedTech Lifen raises €50M
Leading MedTech Lifen raises €50M
Leading MedTech Lifen raises €50M
16 November 2021
Caresyntax Extends Series C to Total Raise of $130 million
Caresyntax Extends Series C to Total Raise of $130 million
Caresyntax Extends Series C to Total Raise of $130 million
16 September 2021
Press Release Groupe PSIH
Press Release Groupe PSIH
Press Release Groupe PSIH
14 September 2021
Sifted – Caresyntax secures $100m for AI hospital operating tech
Sifted – Caresyntax secures $100m for AI hospital operating tech
Sifted – Caresyntax secures $100m for AI hospital operating tech
29 April 2021
Fierce Healthtech – Caresyntax hauls in $100m to expand
Fierce Healthtech – Caresyntax hauls in $100m to expand
Fierce Healthtech – Caresyntax hauls in $100m to expand
28 April 2021
Fierce Biotech – LUMICKS snags £93M for its molecular tweezers and cell therapy hardware
Fierce Biotech – LUMICKS snags £93M for its molecular tweezers and cell therapy hardware
Fierce Biotech – LUMICKS snags £93M for its molecular tweezers and cell therapy hardware
19 April 2021
Lauxera
Lauxera tops target for sophomore fund
Lauxera tops target for sophomore fund
Lauxera tops target for sophomore fund
6 October 2025
Impact and financial returns: a winning combination
Impact and financial returns: a winning combination
Impact and financial returns: a winning combination
15 March 2024
Pierre Moustial on BFM Business – Check-up Santé
Pierre Moustial on BFM Business – Check-up Santé
Pierre Moustial on BFM Business – Check-up Santé
9 March 2024
Lauxera’s charitable partnership with Institut Imagine is explained in this interview with Stanislas Lyonnet and Pierre Moustial
Lauxera’s charitable partnership with Institut Imagine is explained in this interview with Stanislas Lyonnet and Pierre Moustial
Lauxera’s charitable partnership with Institut Imagine is explained in this interview with Stanislas Lyonnet and Pierre Moustial
4 March 2024
Lauxera Capital Partners signs a partnership with Institut Imagine to fund groundbreaking research into rare diseases
Lauxera Capital Partners signs a partnership with Institut Imagine to fund groundbreaking research into rare diseases
Lauxera Capital Partners signs a partnership with Institut Imagine to fund groundbreaking research into rare diseases
10 October 2023
Lauxera Capital Partners – Press release – Final closing
Lauxera Capital Partners – Press release – Final closing
Lauxera Capital Partners – Press release – Final closing
8 February 2022
Pierre Moustial Interview
Pierre Moustial Interview
Pierre Moustial Interview
11 October 2021
ESG & Impact
Biomedicaments : Verdot to invest €10 million in new plant in Puy-de-Dôme
Biomedicaments : Verdot to invest €10 million in new plant in Puy-de-Dôme
Biomedicaments : Verdot to invest €10 million in new plant in Puy-de-Dôme
23 September 2024
Impact and financial returns: a winning combination
Impact and financial returns: a winning combination
Impact and financial returns: a winning combination
15 March 2024
Close Menu
LP Portal
About us
Team
Portfolio
Stories
ESG & Impact
News
Contact
Linkedin
LP Portal
We use cookies to ensure you get the best experience on our website. If you continue to use this site, we will assume that you are happy with it.
OK
Personal data
